Management of IBD Patients During the COVID-19 Pandemic.
作者信息
Lichtenstein Gary R
机构信息
Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia, Pennsylvania.
出版信息
Gastroenterol Hepatol (N Y). 2020 Nov;16(11):577-580.
Abstract
摘要
相似文献
1
Management of IBD Patients During the COVID-19 Pandemic.
Gastroenterol Hepatol (N Y). 2020 Nov;16(11):577-580.
2
Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.罗马尼亚一家三级胃肠病学中心的炎症性肠病管理：COVID-19 大流行的挑战。
J Gastrointestin Liver Dis. 2020 Dec 12;29(4):549-553. doi: 10.15403/jgld-3183.
3
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center.新冠疫情对一家大型炎症性肠病（IBD）中心IBD内镜检查程序的影响。
Endosc Int Open. 2020 Jul;8(7):E980-E984. doi: 10.1055/a-1183-3073. Epub 2020 Jun 23.
4
Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey.西班牙炎症性肠病单位应对 COVID-19 大流行的管理：一项全国性调查的结果。
Inflamm Bowel Dis. 2020 Jul 17;26(8):1149-1154. doi: 10.1093/ibd/izaa142.
5
A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol.COVID-19疫情期间炎症性肠病患者管理支持系统：伊朗经验——研究方案
Middle East J Dig Dis. 2020 Oct;12(4):238-245. doi: 10.34172/mejdd.2020.188.
6
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.接受免疫抑制药物治疗的炎症性肠病患者：大流行期间对 COVID-19 及医疗服务的看法。
Scand J Gastroenterol. 2021 May;56(5):545-551. doi: 10.1080/00365521.2021.1901308. Epub 2021 Mar 26.
7
Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients.新冠疫情爆发前及期间炎症性肠病患者的残疾状况与生活质量：一项横断面研究
Saudi J Gastroenterol. 2020 Sep-Oct;26(5):256-262. doi: 10.4103/sjg.SJG_175_20.
8
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care.意大利 2019 冠状病毒病封锁期间和之后与炎症性肠病管理相关的活动：如何保持护理标准。
United European Gastroenterol J. 2020 Dec;8(10):1228-1235. doi: 10.1177/2050640620964132. Epub 2020 Oct 18.
9
Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study.远程医疗时代炎症性肠病患者对新冠疫情的认知：横断面问卷调查研究
J Med Internet Res. 2020 Nov 2;22(11):e19574. doi: 10.2196/19574.
10
The Greek Response to COVID-19: A True Success Story from an IBD Perspective.从炎症性肠病角度看希腊对 COVID-19 的应对：一个真正的成功案例。
Inflamm Bowel Dis. 2020 Jul 17;26(8):1144-1148. doi: 10.1093/ibd/izaa143.
本文引用的文献
1
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
2
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
3
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
4
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.COVID-19 重症患者中氢化可的松对 21 天死亡率或呼吸支持的影响：一项随机临床试验。
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
5
Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician.冠状病毒与炎症性肠病患者：临床医生的管理策略
Am J Gastroenterol. 2020 Oct;115(10):1566-1569. doi: 10.14309/ajg.0000000000000817.
6
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下：一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
7
Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes.轻度疾病严重程度的 COVID-19 患者的消化症状：临床表型、粪便病毒 RNA 检测和结局。
Am J Gastroenterol. 2020 Jun;115(6):916-923. doi: 10.14309/ajg.0000000000000664.
8
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
9
Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.74 例伴有胃肠道症状的 2019 年冠状病毒病（COVID-19）患者的流行病学、临床和病毒学特征。
Gut. 2020 Jun;69(6):1002-1009. doi: 10.1136/gutjnl-2020-320926. Epub 2020 Mar 24.
10
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA在粪便样本中的长期存在。
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435. doi: 10.1016/S2468-1253(20)30083-2. Epub 2020 Mar 20.
Zotero 插件